-
Mashup Score: 0International Liver Congress - 11 month(s) ago
Highlights from the EASL Congress, including perspectives and interviews with leading researchers and clinicians.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0
Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress. “As a physician, I know how important it is to provide patients with therapies that can be impactful across a broad population of individuals with NASH,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Pegozafermin improves #fibrosis, shows promise as ‘mainstay treatment’ for #NASH @DrLoomba #EASLCongress #EASL23 #LiverTwitter https://t.co/PrrfrRngNV
-
-
Mashup Score: 0Pegozafermin: An “Entriguing” New Therapy for High Triglycerides - 11 month(s) ago
In contrast to high levels of low-density lipoprotein cholesterol (LDL-C), where reduction invariably results in clinical benefit (irrespective of the therapy/therapies used), the impact of lowerin…
Source: hyhCategories: Cardiologists, Latest HeadlinesTweet-
Pegozafermin: An "Entriguing" New Therapy for High Triglycerides https://t.co/GMsSsVsJH9 @PennMedicine @AHAPennsylvania @PennCardiology @VAPhiladelphia @nationallipid @ASPCardio @DLBHATTMD @JohnKastelein @TriglycerideF @readersdigest #triglycerides #NASH @NatureMedicine https://t.co/MK7BV9DT11
-
-
Mashup Score: 0Intercept pivots away from NASH following second FDA rejection for obeticholic acid - 11 month(s) ago
The FDA issued a complete response letter to Intercept indicating it cannot approve the company’s new drug application for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: @InterceptPharma pivots away from #NASH following second @US_FDA rejection for #obeticholicacid #LiverTwitter #MedTwitter #FDA https://t.co/BmIxBOzgQo
-
-
Mashup Score: 0Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement - 11 month(s) ago
Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results. “Resmetirom is an oral, once-daily liver-targeted [thyroid hormone receptor]-beta- selective agonist in development for NASH,” Stephen A.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from #EASLCongress: #Resmetirom achieves ‘meaningful effects’ on #NASH resolution, #fibrosis stage improvement @EASLnews @MadrigalPharma #LiverTwitter https://t.co/LmpzoRMS6o
-
-
Mashup Score: 0Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement - 11 month(s) ago
Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results. “Resmetirom is an oral, once-daily liver-targeted [thyroid hormone receptor]-beta- selective agonist in development for NASH,” Stephen A.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Both 80 mg and 100 mg doses of #resmetirom achieved #liverbiopsy endpoints at 52 weeks in patients with #NASH and had a safety profile consistent with previous reports, according to primary #MAESTRO-NASH trial results. @MadrigalPharma https://t.co/07uZdb0AzJ
-
-
Mashup Score: 0Home - 11 month(s) ago
IMPORTANT INFORMATIONThis symposium will be offered both in-person and virtually and is an Integrated Symposium of the International Liver Congress™ 2023, 59th Annual Meeting of the European Association for the Study of the Liver (EASL). PLEASE NOTE: Only registered attendees of the International Liver Congress™ 2023, 59th Annual Meeting of the European Association for the Study of the Liver…
Source: na.eventscloud.comCategories: Dermatology, Latest HeadlinesTweet-
DON'T MISS: Learn the requirement to screen individuals at risk of nonalcoholic steatohepatitis #NASH 📆 June 24, 2023 🌟 1.0 CME Credit 📍 https://t.co/Lv2zVp6edI https://t.co/7HltC5lx9P
-
-
Mashup Score: 0Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement - 11 month(s) ago
Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results. “Resmetirom is an oral, once-daily liver-targeted [thyroid hormone receptor]-beta- selective agonist in development for NASH,” Stephen A.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Resmetirom achieves ‘meaningful effects’ on #NASH resolution, #fibrosis stage improvement #LiverTwitter #EASLCongress @MadrigalPharma https://t.co/07uZdb0AzJ
-
-
Mashup Score: 0Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement - 11 month(s) ago
Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results. “Resmetirom is an oral, once-daily liver-targeted [thyroid hormone receptor]-beta- selective agonist in development for NASH,” Stephen A.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Both 80 mg and 100 mg doses of #resmetirom achieved liver biopsy endpoints at 52 weeks in patients with #NASH and had a safety profile consistent with previous reports, according to primary #MAESTRO-NASH trial results. @MadrigalPharma #EASLCongress https://t.co/LmpzoRMS6o
-
-
Mashup Score: 0Lead NASH contender falls short for FDA: Could NAFLD name change shift the status quo? - 11 month(s) ago
In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA finish line. Last month, the FDA rejected the lead NASH drug contender, obeticholic acid, due to concerns that its risks outweigh its benefits. This action leaves Madrigal Pharmaceuticals’
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Lead #NASH contender falls short for @US_FDA: Could #NAFLD name change shift the status quo? #GITwitter #MedTwitter https://t.co/dh2j2TaFhZ
-
#EASLCongress 2023 may be over, but we’ve got you covered! Check out all the latest #research on #hepatitis, #NASH, #NAFLD (or, #MALD now!!) and more you may have missed!! https://t.co/41frjhVkrJ https://t.co/UscKnJc0cP